Cannara Biotech, a vertically integrated cannabis producer with two mega facilities in Québec spanning more than 1,600,000 square feet, has entered into a long-term international supply agreement with Curaleaf International Limited for the production and supply of bulk cannabis flower destined for international markets.
The agreement, if fully realized, has a potential aggregate contract value of up to CAD$21 million over the term of the deal, based on committed supply volumes and the terms and conditions of the agreement, according to the company. It's Cannara’s first long-term supply commitment for international markets.
In connection with this opportunity, Cannara has activated two additional cultivation zones at its Valleyfield facility during fiscal third quarter 2026, bringing its total zones in production to 14 out of 24 grow zones of 25,000 square feet each. To meet anticipated commercial demand, the company expects to activate four additional cultivation zones by the end of fiscal 2027.
Once complete, this expansion is projected to increase annual production capacity to 75,000 kilograms, enabling Cannara to reach its targeted production capacity approximately one year ahead of its original fiscal 2028 timeline.
As part of the deal, Curaleaf will support Cannara’s pursuit of EU-GMP certification of its processing center at the Valleyfield facility. In the interim, all cannabis flower supplied under the agreement will be fully dried and processed under EU-GMP conditions at Curaleaf’s EU-GMP certified facility in Canada prior to release into international medical markets.
